蜈蚣提取液对乳腺癌细胞株MDA-MB-231体外抗癌作用的研究
摘要
目的：研究蜈蚣提取液对乳腺癌细胞株的敏感性,为乳腺癌的临床治疗提供理论依据。
方法：体外培养乳腺癌细胞株MDA-MB-231,采用不同浓度蜈蚣提取液(Extract of Centipede, ECP)予以干预,通过MTT实验、细胞的药物浓度-时间生长曲线研究其对乳腺癌细胞株的敏感性；利用倒置光学显微镜和电子显微镜观察细胞形态及其超微结构的变化。
结果：①MTT法揭示各浓度ECP对人乳腺癌细胞株MDA-MB-231生长均有抑制作用。ECP在80mg/ml、40 mg/ml、20 mg/ml、10mg/ml、5 mg/ml、2.5 mg/ml及1.25 mg/ml下对MDA-MB-231细胞的抑制率依次为(71.26±2.64)%、(62.48±6.67)%、(56.26±3.17)%、(48.63±4.48)%、(42.13±4.73)%、(34.5±2.98)%和(26.89±2.95)%,各组间有显著差异性(P<0.01); ECP在80mg/ml浓度组的抑制率与吡柔比星(THP) 10μg/ml抑制率比较无统计学差异(P>0.05),大致相同；ECP在20mg/ml及40mg/ml组的抑制率与THP5μg/ml抑制率比较无统计学差异(P>0.05),大致相同；由公式计算得出的中效浓度为12.5mg/ml。②细胞生长曲线图显示MDA-MB-231活细胞数目与ECP浓度及药物作用时间相关。治疗组浓度在12.5mg/ml与25mg/ml时,用药后24小时活细胞数就显著减少。各组间活细胞数比较差异明显(P<0.01)。③光镜下见ECP作用48小时后,浓度低于10mg/ml对MDA-MB-231细胞抑制作用不明显,浓度在10mg/ml以上时,MDA-MB-231活细胞数减少,细胞形态变圆变小,80mg/ml时见细胞大片坏死,有较多的不规则细胞碎片,培养瓶中坏死脱落细胞增多。电镜下见治疗组细胞密度增高,染色质凝集固缩,染色质边集,核固缩、核碎裂,及凋亡小体的形成。
结论：①ECP能抑制人乳腺癌细胞株MDA-MB-231的增殖,且抑制作用呈剂量和时间依赖效应；②ECP低浓度有诱导MDA-MB-231细胞凋亡作用,中、高浓度有直接杀伤MDA-MB-231细胞作用。
Objective:To investigate sensitivity of the effect of centipede extract on breast cancer cell lines and provide evidences for further clinic therapy of breast cancer
Methods:Cultured breast cancer cells MDA-MB-231 are intervened with different concentration of centipede extract. MTT assay and concentration-time curve are used to study the effect sensitivity of centipede extract on breast cancer cell lines; Inverted light microscope and electron microscope are used to observe cell changes in morphology and ultrastructure.
Results:①The results of MTT assay showed that different concentrations of centipede extract all can inhibit the growth of human breast cancer cells MDA-MB-231.The inhibition rates were (71.26±2.64)%, (62.48±6.67)%, (56.26±3.17)%, (48.63±4.48)%, (42.13±4.73)%, (34.5±2.98)% and (26.89±2.95)% respectively,while the Corresponding concentration of centipede extract were 80mg/ml,40 mg/ ml,20 mg/ml, 10mg/ml,5 mg/ml,2.5 mg/ml and 1.25 mg/ml,and each group had significant differences(P<0.01). ECP concentrations in 80mg/ml inhibition rate of pirarubicin (THP) 10μg/ml was no significant difference in inhibition rate(P>0.05), roughly the same, ECP in the inhibition of 20mg/ml and 40mg/ml group rate and THP5μg/ml no significant difference in inhibition rate (P>0.05), roughly the same. IC50 of centipede extract to MDA-MB-231 was 12.5mg/ml.②Drug concentration-time curve revealed that the viable cell counts of MDA-MB-231 has direct relations with the concentration and administrative time of centipede extract. When treated with 12.5mg/ml and 25mg/ml centipede extract, viable counts of MDA-MB-231 sharply decrease after 24 hours treatment and the difference among treatment groups is significant (P<0.01).③After 48hr intervention, there were no inhibitory effect observed by light microscopy in groups with concentration less than 10mg/ml; viable counts of MDA-MB-231 decreased and the cells transformed to round and small when concentration were more than 10mg/ml; With treated with 80mg/ml, large number of necrotic cells and irregular cell debris were seemed. Meanwhile, margination and condensation of chromatin, fragmentation and condensation of nucleus and formation of apoptotic bodies were found in cells by electron microscope which had higher density.
Conclusion:①Extract of centipede can inhibit the growing of human breast cancer cells MDA-MB-231 and the effect was concentration-time dependent;②Extract of centipede can induce MDA-MB-231 cell line to apoptosis in low concentration and directly kill it in middle or high concentration.
方法：体外培养乳腺癌细胞株MDA-MB-231,采用不同浓度蜈蚣提取液(Extract of Centipede, ECP)予以干预,通过MTT实验、细胞的药物浓度-时间生长曲线研究其对乳腺癌细胞株的敏感性；利用倒置光学显微镜和电子显微镜观察细胞形态及其超微结构的变化。
结果：①MTT法揭示各浓度ECP对人乳腺癌细胞株MDA-MB-231生长均有抑制作用。ECP在80mg/ml、40 mg/ml、20 mg/ml、10mg/ml、5 mg/ml、2.5 mg/ml及1.25 mg/ml下对MDA-MB-231细胞的抑制率依次为(71.26±2.64)%、(62.48±6.67)%、(56.26±3.17)%、(48.63±4.48)%、(42.13±4.73)%、(34.5±2.98)%和(26.89±2.95)%,各组间有显著差异性(P<0.01); ECP在80mg/ml浓度组的抑制率与吡柔比星(THP) 10μg/ml抑制率比较无统计学差异(P>0.05),大致相同；ECP在20mg/ml及40mg/ml组的抑制率与THP5μg/ml抑制率比较无统计学差异(P>0.05),大致相同；由公式计算得出的中效浓度为12.5mg/ml。②细胞生长曲线图显示MDA-MB-231活细胞数目与ECP浓度及药物作用时间相关。治疗组浓度在12.5mg/ml与25mg/ml时,用药后24小时活细胞数就显著减少。各组间活细胞数比较差异明显(P<0.01)。③光镜下见ECP作用48小时后,浓度低于10mg/ml对MDA-MB-231细胞抑制作用不明显,浓度在10mg/ml以上时,MDA-MB-231活细胞数减少,细胞形态变圆变小,80mg/ml时见细胞大片坏死,有较多的不规则细胞碎片,培养瓶中坏死脱落细胞增多。电镜下见治疗组细胞密度增高,染色质凝集固缩,染色质边集,核固缩、核碎裂,及凋亡小体的形成。
结论：①ECP能抑制人乳腺癌细胞株MDA-MB-231的增殖,且抑制作用呈剂量和时间依赖效应；②ECP低浓度有诱导MDA-MB-231细胞凋亡作用,中、高浓度有直接杀伤MDA-MB-231细胞作用。
Objective:To investigate sensitivity of the effect of centipede extract on breast cancer cell lines and provide evidences for further clinic therapy of breast cancer
Methods:Cultured breast cancer cells MDA-MB-231 are intervened with different concentration of centipede extract. MTT assay and concentration-time curve are used to study the effect sensitivity of centipede extract on breast cancer cell lines; Inverted light microscope and electron microscope are used to observe cell changes in morphology and ultrastructure.
Results:①The results of MTT assay showed that different concentrations of centipede extract all can inhibit the growth of human breast cancer cells MDA-MB-231.The inhibition rates were (71.26±2.64)%, (62.48±6.67)%, (56.26±3.17)%, (48.63±4.48)%, (42.13±4.73)%, (34.5±2.98)% and (26.89±2.95)% respectively,while the Corresponding concentration of centipede extract were 80mg/ml,40 mg/ ml,20 mg/ml, 10mg/ml,5 mg/ml,2.5 mg/ml and 1.25 mg/ml,and each group had significant differences(P<0.01). ECP concentrations in 80mg/ml inhibition rate of pirarubicin (THP) 10μg/ml was no significant difference in inhibition rate(P>0.05), roughly the same, ECP in the inhibition of 20mg/ml and 40mg/ml group rate and THP5μg/ml no significant difference in inhibition rate (P>0.05), roughly the same. IC50 of centipede extract to MDA-MB-231 was 12.5mg/ml.②Drug concentration-time curve revealed that the viable cell counts of MDA-MB-231 has direct relations with the concentration and administrative time of centipede extract. When treated with 12.5mg/ml and 25mg/ml centipede extract, viable counts of MDA-MB-231 sharply decrease after 24 hours treatment and the difference among treatment groups is significant (P<0.01).③After 48hr intervention, there were no inhibitory effect observed by light microscopy in groups with concentration less than 10mg/ml; viable counts of MDA-MB-231 decreased and the cells transformed to round and small when concentration were more than 10mg/ml; With treated with 80mg/ml, large number of necrotic cells and irregular cell debris were seemed. Meanwhile, margination and condensation of chromatin, fragmentation and condensation of nucleus and formation of apoptotic bodies were found in cells by electron microscope which had higher density.
Conclusion:①Extract of centipede can inhibit the growing of human breast cancer cells MDA-MB-231 and the effect was concentration-time dependent;②Extract of centipede can induce MDA-MB-231 cell line to apoptosis in low concentration and directly kill it in middle or high concentration.
引文
[1]Law RenceW,Norton,李芬芳等.美国乳腺癌治疗现状[J].陕西肿瘤医学,2000,8(2)：123.
[2]Chow LWC,LooWTY. The differential effects of cyclophosphamide, epirubicinand-fluorouracil on apoptotic marker (CPP-32), pro-ap-optotic protein (p21waf-1) and anti-apoptotic protein (bcl-2) in breast cancer cells[J].Breast Cancer Res Treat,2003,80 (3):239-244.
[3]陈孝平,石应康,邱贵兴,主编.外科学[M].北京：人民卫生出版社,2005,439.
[4]常卫华,王留兴等.乳腺癌分子靶向治疗的进展与展望[J].肿瘤基础与临床,2009,22(3)：270-271.
[5]Jacobs JR,Bovasso GB.Early and chronic stress and their relation to breast cancer[J].PsycholMed,2004,30(3):669-678.
[6]朱珍,张凤春.晚期乳腺癌的化疗进展[J].现代肿瘤医学,2009,17(6)：1179-1181.
[7]徐兵河.复发转移乳腺癌的化学治疗[J].中国实用内科杂志,2007,27：24.
[8]Early Breast Cancer TrialistsI Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:An overview of the randomised trials [J]. Lancet,2005,365 (9742): 1687-1717.
[9]Blum JL,DierasV,Lo Russo PM, et al. Multicenter, phase Ⅱ study of capecitabine in taxane-pretreated etastatic breast carcinoma patients[J]. Cancer, 2001,92:1759-1768.
[10]Vahdat LT, Tomas E, Li R, et al. Phase Ⅲ trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with mestastatic breast cancer(MBC) previously treated or resistant to an anthracycline and resistant to taxanes[J].Proc Am Soc Clin Oncol,2007,25(18s):33s.
[11]李庆,范晓磊.中药抗肿瘤的研究进展[J].中国微生态学杂志,2007,19(3)：317-318.
[12]陈红琳,李小莉,甘明.墨江蜈蚣的药理作用[J].湖北中医杂志,2003,25(1)：501.
[13]梁洁,黄华营.药用蜈蚣的化学成分及药理活性研究近况[J].广西中医药,2005,28(4)：6-7.
[14]张维文,罗健东,张贵平.蜈蚣水提物对动物消化功能的增强作用[J].中药材,1999,22(10)：518-519.
[15]贺巍,叶海英.中药蜈蚣的研究进展[J].中药材,2002,25(2)：152-155.
[16]潘启超,胥彬主编.肿瘤药理学与化疗学第二版[M].河南医科大学出版社,郑州,2000；315.
[17]李厚伟,张妍,许超千,等.中药HB对喉癌Hep22细胞的抑制作用及其机制研究[J].哈尔滨医科大学学报,2001,35(4)：261-262.
[18]刘国清,田秉漳,皮执民,等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[19]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖南中医志,2004,20(5)：57-58.
[20]司秋菊,王鑫国,白霞,等.蜈蚣对动脉粥样硬化家兔血液流变学的影响[J].中国老年学杂志,2004,24(9)：831-833.
[21]焦波,娄红祥,王东兴,等.蜈蚣提取液对小鼠精原细胞的作用[J].山东医科大学学报,1999,37(4)：358.
[22]司徒镇强,吴军正.细胞培养[M].西安：世界图书出版公司,2004,1-37.
[23]赵满仓,魏文清等.MTT法抗肿瘤药敏试验影响因素的探讨[M].临床肿瘤学杂志,2009,14(4)：306-308.
[24]Khar A,Alia AM,Pardhasaradhi BV,et al.Induction of stress recsponse renders human tumor cell lines resistant to curcumin-mediated apoptosis:Role of reactive oxygen intermediates[J].Cell Stress Chaperones,2001;694:368-7.
[25]R.A Weinberg著,詹启敏,刘芝华主译.癌生物学[M].北京科学出版社,2009,716-717.
[26]吴达龙,黄丰,吕焕章.乳腺癌耐药蛋白——肿瘤多基因耐药研究新进展[J].癌症,2003,22(4)：441-444.
[27]McGrogan G, Rudolph P. Mascarel Ⅱ DNA topoisomerase expression and the response to primary chemotherapy inbreast cancer [J]. Br J Cancer,2003,89: 666-671.
[28]Hayes DF, Thor A, Dressler I, et al. HER-2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer CALGB 9344 [J]. Proc Am Soc Clin Oncol,2006,24 (18S):510.
[29]韩双红.蜈蚣的研究进展.天津药学,2002,14(5)：131.
[30]刘峰.蜈蚣的临床应用及其毒性研究.广西中医药,1999,22(4)：521.
[41]李厚伟,张妍,许超千,等.中药HB对喉癌Hep22细胞的抑制作用及 其机制研究[J].哈尔滨医科大学学报,2001,35(4)：261-262
[32]Henrik Mueller, Matthias U Kassack, Michael Wiese. Comparison of the usefulness of the MTT, ATP, and ealcein assays to predict the potency of cytotoxic agents in various human cancer cell lines[J]. J Biomol Screen,2004,9:506-515.
[33]Morizane Y,Honda R,Fukami K,et al.X-linked inhibitor of apoptosis functions as ubiquitin ligase to ward mature caspase-9 and cytosolic Smac/DIABLO[J].J Biochem (Tokyo),2005,137:125-132.
[1]Law RenceW,Norton,李芬芳,等.美国乳腺癌治疗现状[J].陕西肿瘤医学,2000,8(2)：123.
[2]Chow LWC,LooWTY. The differential effects of cyclophosphamide,ep irubicinand-fluorouracil on apoptotic marker (CPP-32), pro-ap-optotic protein (p21waf-1) and anti-apoptotic protein (bcl-2) in breast cancer cells [J]. Breast Cancer Res Treat,2003,80 (3):239-244.
[3]董志伟,乔友林等.中国癌症高发现场报告[J].中国肿瘤,2009,18(1)：4-9.
[4]陈孝平,石应康,邱贵兴,主编.外科学[M].北京：人民卫生出版社,2005.439.
[5]常卫华,王留兴等.乳腺癌分子靶向治疗的进展与展望[J].肿瘤基础与临床,2009,22(3)：270-271.
[6]Jacobs JR,Bovasso GB. Early and chronic stress and their relation to breast cancer[J]. PsycholMed,2004,30 (3):669-678.
[7]朱珍,张凤春.晚期乳腺癌的化疗进展[J].现代肿瘤医学,2009,17(6)：1179-1181.
[8]徐兵河.复发转移乳腺癌的化学治疗[J].中国实用内科杂志,2007,27：24.
[9]商宏恺,童晓文.乳腺癌手术治疗的演变[M].中国实用妇产与产科杂志,2008,24(11)：808-810.
[10]HalstedWS. The results of operations for cancer of breast performed at the Johns Hopkins hospital from June1889 to January1889 [J].Joh Hop Bul,1894,4:294.
[11]Urban JA,Baker HW. Radical mastectomy with en bloc resection of the Intelmammary lymph node chain:a new procedure for primary operable cancer of the breast[J]. Cancer,1952,5 (5):992-1008.
[12]Fisher B, Jeong J H,Anderson S,et al.Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation[J]. N Engl J Med,2002,347 (8):567.
[13]王先明.乳腺癌手术治疗的历史演变与现代进展[J].中国现代手术学杂志,2003,7(6)：467-471.
[14]Smit JJ, SchinkelAH,Oude Elferink RPJ, et al. Homozygous disruption of the murine mdrz pglycop rotein gene leads to a comp lete absence of phospholip id from bile and to liver disease[J]. Cell,1993,75(3):451-462.
[15]Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer:long-term results of a randomized trial. Eur J Cancer,1990,26:668-670.
[16]Fisher B, Anderson S, Redmond CK, et al. Reanalysis and result s after 12 years of follow-up in a randomized clinical trial comparing total mastectomy wit h lumpectomy wit h orwit hout irradiation in the treatment of breast cancer [J]. NEngl J Med,1995; 333 (22):1456-1461
[17]National Surgical Adjuvant Breast and Bowel Project (NSABP). Progress Report [R]. July 1998:31-39.
[18]Sarrazin D, Arriagada R, Contesso G, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol,1989,14:177-184.
[19]Cutuli B,Nir CCS,Lafontan BD,et al.Brast-conserving therapy for ductal carcinoma in situ of the Breast:the French Cancer centers experience[J].Int J Radia Oncol Biol Phys,2002,53:868-879.
[20]Hiotic K,Ye W, Sposto R,et al.Predictors of breast conservation the rapy size is not all thatmatters[J]. Cancer,2005,103(5):892-899.
[21]叶再元,蒋劲松.乳腺癌外科治疗新进展[J].现代实用医学,2005,17(12)：730-732.
[22]郭小毛,梅欣等.局部晚期乳腺癌的治疗进展[J].中国癌症杂志,2006,16(6)：409-416.
[23]Reed J, Rosman M, Verbanac KM, et al. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer:10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study[J]. J Am Coll Surg,2009,208(3):333-340.
[24]Sato K, Shigenaga R. Sentinel lymph node biopsy for breast cancer[J]. J Surg Oncol,2007,96:322-329.
[25]邵志敏,沈镇宙.21世纪乳腺癌治疗的展望[M].中国癌症杂志,2005,15(5)： 405-407
[26]Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemot-herapy. Danish Breast Cancer Cooperative Group 8-b Trial [J]. N Engl J Med,1997; 337 (14):949-955.
[27]Whelan TJ,J ulian J,Wright J,et al.Does locoregional radiation therapy improve survival in breast cancer?A meta-analysis Ameta-analysis [J].J Clin Oncol, 2000; 18 (6):1220-1229.
[28]Recht A,Edge SB,Solin LJ,et al.Postmastectomy radiotherapy:clinical practice guidelines of the American Society of Clinical Oncology [J].J Clin Oncol,2001;19(5):1539-1569.
[29]于世英.放疗在乳腺癌治疗中作用[J].临床外科杂志,2000,8(5)：261.
[30]薛军,程晶等.不同放化疗模式治疗局部晚期乳腺癌的疗效分析[J].肿瘤防治研究,2009,36(10)：876-878.
[31]余子豪,乳腺癌.[M]殷蔚伯,谷铣之.肿瘤放射治疗学.3版.北京：中国协和医科大学出版社,2002：1077-1078.
[32]Early Breat Cancer TrialistsI Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:An overview of the randomised trials [J].Lancet,2005, 365 (9742):1687-1717.
[33]Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer the results of 20 years of follow-up [J]. N Engl J Med,1995,332 (14):901.
[34]Bonadonna G, Moliterni A, Zambetti M, et al.30 years follow up of randomized studies of adjuvant CMF in operable breast cancer, cohort study[J]. BMJ,2005,330:217.
[35]Early Breast Cancer Trialists's Collaborative Group. Multi-agent chemotherapy for early breast cancer [DB/CD]. Cochrane Database Syst Rev,2002, (1):CD000487.
[36]Poole CJ, Earl HM, Hiller L, et al.Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as adjuvant therapy for early breast cancer [J]. N Engl J Med,2006,355 (18):1851-1862.
[37]Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J].J Clin Oncol,2003,21 (6):976-983.
[38]Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after Doxorubicin plus Cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:Results from NSABP B-28 [J]. J Clin Oncol,2005,23 (16): 3686-3696.
[39]Jones S, Holmes F, O'Shaughnessy J, et al. Extended followup and analysis by age of the US oncology adjuvant trial 9735:Docetaxel/ Cyclophosphamide is associated with an OS benefit compared to Doxorubicin Cyclophosphamide and is welltolerated in women 65 or older. Paper presented at San Antonio Breast Cancer Symposium [C]. San Antonio, Texas, USA,2007.
[40]Jones SE, Savin MA, Holmes FA, et al. Phase Ⅲ trial comparing Doxorubicin plus Cyclophosphamide with Docetaxel plus Cyclophosphamide as adjuvant therapy for operable breast cancer [J]. J Clin Oncol,2006,24 (34): 5381-5387.
[41]Nabholtz JM, Pienkowski T, Mackey J, et al. Phase Ⅲ trial comparing TAC (Docetaxel, Doxorubicin, Cyclophosphamide) with FAC (5-Fluorouracil, Doxorubicin, Cyclophosphamide) in adjuvant treatment of node positive breast cancer patients:Interim analysis of the BCIRG 001 study [J]. Pro Am Soc Clin Oncol, 2002,21 (1):36.
[42]Ferguson T, Wilcken N, Vagg R, et al. Taxanes for adjuvant treatment of early breast cancer [DB/CD]. Cochrane Database Syst Rev,2007, (4): CD004421.
[43]PiccartMJ, Burzykowski T, Sledge G, et al. Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer: An analysis of 4,256 patients randomized in 12 trials [J]. Breast Cancer ResTreat, 2005,94:S278.
[44]Blum JL,DierasV,Lo Russo PM, et al. Multicenter, phase Ⅱ study of capecitabine in taxane-p retreated etastatic breast carcinoma patients [J]. Cancer, 2001,92:1759-1768.
[45]Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer[J]. Oncology,2001,15:11-14.
[46]FeherO,Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: A multicenter, randomized, phase Ⅲ study[J]. Ann Oncol,2005,16:899-908.
[47]Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase Ⅲ study of gemcitabine p lus paclitaxel (GT) vs paclitaxel (T) as frontline therapy formetastatic breast cancer (MBC):First report of overall survival [J]. Proc Am Soc Clin Oncol, 2004,23:5.
[48]Zelek L,Barthier S, RiofrioM, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma[J]. Cancer,2001,92:2267-2272.
[49]He L,Orr GA, Horwitz SB. Novelmolecules that interact with microtubules and have functional activity similar to Taxol[J]. Drug Discov Today,2001,6:1153-1164.
[50]GradisharW, Krasnojon D, Cheporov S, et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (p ts)with metastatic breast cancer (MBC) [J]. J Clin Oncol, 2007,25(18S):40 s.
[51]Early Breast Cancer Trialists'Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J]. Lancet,2005,365 (9472):1687-1717.
[52]Fisher B,Dignam J,Bryant J,et al. Five versus more t han five years of tamoxifen for lymph node2negative breast cancer:updated findings from the National Surgical Adjuvant Breast and Bowel Project B214 randomized t rial [J]. J N at l Cancer Ⅰ nst,2001,93 (9):684-690.
[53]MillerWR,Dixon JM. Local endocrine effects of aromatase inhibitorswith the breast[J. J Steroid Biochem Mol Biol,2001,79 (1/5):93-102.
[54]The ATAC Trialists Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:100-month analysis of the ATAC trial [J]. Lancet Oncol,2008,9(1):45-53.
[55]CoatesAS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study B IG 1-98 [J]. J Clin Oncol,2007,25 (5):486-492.
[56]王涛,江泽飞.早期乳腺癌术后辅助内分泌治疗的基本原则和新进展[M].肿瘤学杂志,2009,15(9)：783-787.
[57]Vogel C L, Cobleigh M A, Tripathy D, et al. Efficacy and safety of trast uzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol,2002, 20:719-726.
[58]Cameron D, Casey M, Press M, et al. A phase Ⅲ randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab:updated efficacy and biomarker analyses. Breast Cancer Res Treat,2008,112:533-543.
[59]Burris H 3rd, Yardley D, Jones S, et al. Phase Ⅱ trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol,2004,22:1621-1629.
[60]Geyer C E, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER222positive advanced breast cancer. N Engl J Med,2006,355:2733-2743.
[1]韩双红.蜈蚣的研究进展[J].天津药学,2002,14(5)：13-15.
[2]刘峰.蜈蚣的临床应用及毒性研究[J].广西中医药,1999,22(4)：52-53.
[3]杨永华,张水寒,徐琳本,等.僵蚕、蜈蚣提取工艺的研究[J].中国中药杂志,2001,26(9)：599-601.
[4]许鸣镝,柳雪枚.蜈蚣碱性蛋白SSmp-d的分离纯化及其部分理化性质的鉴定[J].生物化学杂志,1997,13(5)：586-591.
[5]曲爱兵,赵维成,梁良,等.蜈蚣组织提取物抗肿瘤活性的初步研究[J].实用肿瘤学杂志,2003,17(1)：29-30.
[6]迟程.墨江蜈蚣和少棘蜈蚣蚣总油脂化学成分比较[J].中草药,1992,23(2)：104.
[7]方红,邓芬,严宜昌,等.黑头蜈蚣的化学成分[J].中药材,1999,22(5)：226-228.
[8]方红,邓芬,严宜昌,等.多棘蜈蚣化学成分的研究[J].中国医学杂志,1997,32(4)；202-203.
[9]张保国,张大禄.动物药[M].北京：中国医药科技出版社,2003,875.
[10]肖培根.新编中药志(第四卷)[M].北京：化学工业出版社,2002,330.
[11]周莉莉,黄迎春,任超.蜈蚣醇提取物和水提取物部分药理作用比较[J].时珍国医国药,2008,19(11)：2697-8.
[12]迟程,罗天浩.蜈蚣毒性与用量的探讨[J].中国中药杂志,1995,15(6)：90-91.
[13]刘峰.蜈蚣的临床应用及其毒性研究[J].广西中医药,1999,22(4)：52-53.
[14]宋建徽,孟祥琴,王永利.蜈蚣提取液的中枢抑制作用及急性毒性[J].河北中医学院学报,1995,16(2)：91-92.
[15]韩双红.蜈蚣的研究进展[J].天津药学2002,14(5)：13-15.
[16]迟程,舒晔,迟萍.墨江蜈蚣和少棘蜈蚣抗惊厥药效学实验研究[J].云南中医学院学报,1992,15(1)：23-24.
[17]陈红琳,李小莉,甘明.墨江蜈蚣的药理作用[J].湖北中医杂志,2003,25(1)：501.
[18]司秋菊,王鑫国,白霞,等.蜈蚣对动脉粥样硬化家兔血液流变学的影响[J].中国老年学杂志,2004,24(9)：831-833.
[19]司秋菊,王亚利,王鑫国,等.蜈蚣有效成分抗心肌缺血作用的研究[J].河北中医药学报,2001,16(2)：1-3.
[20]司秋菊,王亚利,王鑫国,等.蜈蚣对心肌缺血性损伤小鼠NO及iNOS的影响[J].山东中医杂志,2004,23(8)：492-493.
[21]司秋菊,王鑫国,王亚利,等.蜈蚣对动脉粥样硬化家兔血管内皮细胞功能的影响[J].中药药理与临床,2002,18(6)：28-30.
[22]张艳慧,司秋菊,王鑫国.蜈蚣抗家兔动脉粥样硬化的实验研究[J].中药药理与临床2005；21(1)：26-27.
[23]王亚利,司秋菊,王鑫国,等.蜈蚣对动脉粥样硬化家兔血管平滑肌细胞周期及c-myc基因表达的影响[J].中药药床,2001,17(6)：28-29.
[24]张明泉,王亚利,温瑞书,等.蜈蚣提取液对大鼠心脏血流动力学的作用研究[J].河北中医,2004,26(9)：716-717.
[25]毛小平,陈子君,毛晓建,等.蜈蚣的部分药理研究[J].云南中医学院学报,1999,22(3)：1-4.
[26]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖南中医杂志,2004,20(5)：57-58.
[27]焦波,娄红祥,王东兴,等.蜈蚣提取液对小鼠精原细胞的作用[J].山东医科大学学报,1999,37(4)：358.
[28]李风云,陈浩然,张蓄兰,等.中药制剂抗肿瘤作用的实验研究[J].中医药学报,1999,27(5)：57.
[29]刘德贵,苗艳波,张铁光,等.简述有毒动物药的抗肿瘤作用临床研究[J].吉 林中医药,1998,18(6)：61.
[30]李厚伟,张妍,许超千,等.中药HB对喉癌Hep22细胞的抑制作用及其机制研究[J].哈尔滨医科大学学报,2001,35(4)：261-262.
[31]刘国清,田秉漳,皮执民,等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[32]冉泳禄,吴刚,王金焕,等.墨江蜈蚣与少棘蜈蚣的比较研究Ⅱ[J].动物学研究,1996,17(1)：79.
[33]贺巍,叶海英.中药蜈蚣的研究进展[J].中药材,2002,25(2)：152-155.
[34]毛小平,陈子珺,毛晓健,等.蜈蚣的部分药理研究[J].云南中医学院学报,1999,22(3)：1-3.
[35]李小莉,陈红林,甘民.不同品种蜈蚣的抗炎、镇痛作用[J].中国中药杂志,1996,21(8)：498.
[36]陈红琳,李小莉,甘明.墨江蜈蚣的药理作用[J].湖北中医杂志,2003,25(1)：50-51.
[37]梁洁,黄华营.药用蜈蚣的化学成分及药理活性研究近况[J].广西中医药[J]2005,28(4)：6-7.
[38]张维文,罗健东,张贵平.蜈蚣水提物对动物消化功能的增强作用.[J].中药材,1999,22(10)：518-519.
[39]朱步先.朱良春用药经验[M].上海：上海中医学院出版社,1989 120.
[40]王玉芬,韩双红,曲树明,等.蜈蚣延缓衰老作用的研究[J].中国中药杂志,1994,19(11)：685-687.
[41]任丽虹,郝立君,段国新,等.五倍子、蜈蚣对瘢痕疙瘩成纤维细胞增殖和胶原合成的影响[J].实用美容整形外科杂志,2003,14(6)：324-327.
[42]韩双红,王玉芬,赵泰,等.均肾舒冲剂药理作用的研究[J].中草药,1999,30(4)：282.
[43]方红,邓芬.蜈蚣药材中毒成分组织胺的含量测定[J].中草药,1997,28(8)：472-473.
[44]陶红.牵正蜈蚣散治疗神经系统疾病328例临床体会[J].湖南中医杂志,1990,6(1)：216.
[45]伍玉元.蜈蚣粉致急性肝功能损害2例[J].中国中药杂志,1994,19(1)：50.
[46]赵鹏俊,邹永祥.口服蜈蚣粉致急性肾功能衰竭死亡1例[J].中国中药杂志,1998,23(2)：117.
[47]肖贻纯.蜈蚣、全蝎致神经中毒1例[J].中国中药杂志,1996,21(10)：634.
[48]余圣龙.生蜈蚣致过敏[J].中国中药志,1989,14(5)：56.
[49]陈昕.蜈蚣过敏1例[J].四川中医,1997,15(10)：32.
[50]郭志达,吉小莉,宋建贞,等.中药蜈蚣对大鼠心脏毒性作用的初步研究[J].中国临床药理学与治疗学,2000；5(3)：278.
[51]邓芬,方红,王克勤.中药蜈蚣毒溶血活性试验[J].中药材,1997,20(1)：36-37.
[52]虞国茂,沈康.中药蜈蚣对小鼠胚胎发育的影响[J].解剖学杂志,1994,17(1)：56-59.
[53]迟程,罗天浩.蜈蚣毒性与用量的探讨[J].中国中药杂志,1995,15(6)：90-91.
[54]刘峰.蜈蚣的临床应用及其毒性研究[J].广西中医药,1999,22(4)：52-53.
[55]宋建徽,孟祥琴,王永利.蜈蚣提取液的中枢抑制作用及急性毒性[J].河北中医学院学报,1995,16(2)：91-92.
[56]李小莉,陈红琳,甘民.不同品种蜈蚣的抗炎、镇痛作用[J].中国中药杂志,1996,21(8)：498-499.
[57]韩双红.蜈蚣的研究进展[J].天津药学2002,14(5)： 13-15.
[2]Chow LWC,LooWTY. The differential effects of cyclophosphamide, epirubicinand-fluorouracil on apoptotic marker (CPP-32), pro-ap-optotic protein (p21waf-1) and anti-apoptotic protein (bcl-2) in breast cancer cells[J].Breast Cancer Res Treat,2003,80 (3):239-244.
[3]陈孝平,石应康,邱贵兴,主编.外科学[M].北京：人民卫生出版社,2005,439.
[4]常卫华,王留兴等.乳腺癌分子靶向治疗的进展与展望[J].肿瘤基础与临床,2009,22(3)：270-271.
[5]Jacobs JR,Bovasso GB.Early and chronic stress and their relation to breast cancer[J].PsycholMed,2004,30(3):669-678.
[6]朱珍,张凤春.晚期乳腺癌的化疗进展[J].现代肿瘤医学,2009,17(6)：1179-1181.
[7]徐兵河.复发转移乳腺癌的化学治疗[J].中国实用内科杂志,2007,27：24.
[8]Early Breast Cancer TrialistsI Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:An overview of the randomised trials [J]. Lancet,2005,365 (9742): 1687-1717.
[9]Blum JL,DierasV,Lo Russo PM, et al. Multicenter, phase Ⅱ study of capecitabine in taxane-pretreated etastatic breast carcinoma patients[J]. Cancer, 2001,92:1759-1768.
[10]Vahdat LT, Tomas E, Li R, et al. Phase Ⅲ trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with mestastatic breast cancer(MBC) previously treated or resistant to an anthracycline and resistant to taxanes[J].Proc Am Soc Clin Oncol,2007,25(18s):33s.
[11]李庆,范晓磊.中药抗肿瘤的研究进展[J].中国微生态学杂志,2007,19(3)：317-318.
[12]陈红琳,李小莉,甘明.墨江蜈蚣的药理作用[J].湖北中医杂志,2003,25(1)：501.
[13]梁洁,黄华营.药用蜈蚣的化学成分及药理活性研究近况[J].广西中医药,2005,28(4)：6-7.
[14]张维文,罗健东,张贵平.蜈蚣水提物对动物消化功能的增强作用[J].中药材,1999,22(10)：518-519.
[15]贺巍,叶海英.中药蜈蚣的研究进展[J].中药材,2002,25(2)：152-155.
[16]潘启超,胥彬主编.肿瘤药理学与化疗学第二版[M].河南医科大学出版社,郑州,2000；315.
[17]李厚伟,张妍,许超千,等.中药HB对喉癌Hep22细胞的抑制作用及其机制研究[J].哈尔滨医科大学学报,2001,35(4)：261-262.
[18]刘国清,田秉漳,皮执民,等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[19]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖南中医志,2004,20(5)：57-58.
[20]司秋菊,王鑫国,白霞,等.蜈蚣对动脉粥样硬化家兔血液流变学的影响[J].中国老年学杂志,2004,24(9)：831-833.
[21]焦波,娄红祥,王东兴,等.蜈蚣提取液对小鼠精原细胞的作用[J].山东医科大学学报,1999,37(4)：358.
[22]司徒镇强,吴军正.细胞培养[M].西安：世界图书出版公司,2004,1-37.
[23]赵满仓,魏文清等.MTT法抗肿瘤药敏试验影响因素的探讨[M].临床肿瘤学杂志,2009,14(4)：306-308.
[24]Khar A,Alia AM,Pardhasaradhi BV,et al.Induction of stress recsponse renders human tumor cell lines resistant to curcumin-mediated apoptosis:Role of reactive oxygen intermediates[J].Cell Stress Chaperones,2001;694:368-7.
[25]R.A Weinberg著,詹启敏,刘芝华主译.癌生物学[M].北京科学出版社,2009,716-717.
[26]吴达龙,黄丰,吕焕章.乳腺癌耐药蛋白——肿瘤多基因耐药研究新进展[J].癌症,2003,22(4)：441-444.
[27]McGrogan G, Rudolph P. Mascarel Ⅱ DNA topoisomerase expression and the response to primary chemotherapy inbreast cancer [J]. Br J Cancer,2003,89: 666-671.
[28]Hayes DF, Thor A, Dressler I, et al. HER-2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer CALGB 9344 [J]. Proc Am Soc Clin Oncol,2006,24 (18S):510.
[29]韩双红.蜈蚣的研究进展.天津药学,2002,14(5)：131.
[30]刘峰.蜈蚣的临床应用及其毒性研究.广西中医药,1999,22(4)：521.
[41]李厚伟,张妍,许超千,等.中药HB对喉癌Hep22细胞的抑制作用及 其机制研究[J].哈尔滨医科大学学报,2001,35(4)：261-262
[32]Henrik Mueller, Matthias U Kassack, Michael Wiese. Comparison of the usefulness of the MTT, ATP, and ealcein assays to predict the potency of cytotoxic agents in various human cancer cell lines[J]. J Biomol Screen,2004,9:506-515.
[33]Morizane Y,Honda R,Fukami K,et al.X-linked inhibitor of apoptosis functions as ubiquitin ligase to ward mature caspase-9 and cytosolic Smac/DIABLO[J].J Biochem (Tokyo),2005,137:125-132.
[1]Law RenceW,Norton,李芬芳,等.美国乳腺癌治疗现状[J].陕西肿瘤医学,2000,8(2)：123.
[2]Chow LWC,LooWTY. The differential effects of cyclophosphamide,ep irubicinand-fluorouracil on apoptotic marker (CPP-32), pro-ap-optotic protein (p21waf-1) and anti-apoptotic protein (bcl-2) in breast cancer cells [J]. Breast Cancer Res Treat,2003,80 (3):239-244.
[3]董志伟,乔友林等.中国癌症高发现场报告[J].中国肿瘤,2009,18(1)：4-9.
[4]陈孝平,石应康,邱贵兴,主编.外科学[M].北京：人民卫生出版社,2005.439.
[5]常卫华,王留兴等.乳腺癌分子靶向治疗的进展与展望[J].肿瘤基础与临床,2009,22(3)：270-271.
[6]Jacobs JR,Bovasso GB. Early and chronic stress and their relation to breast cancer[J]. PsycholMed,2004,30 (3):669-678.
[7]朱珍,张凤春.晚期乳腺癌的化疗进展[J].现代肿瘤医学,2009,17(6)：1179-1181.
[8]徐兵河.复发转移乳腺癌的化学治疗[J].中国实用内科杂志,2007,27：24.
[9]商宏恺,童晓文.乳腺癌手术治疗的演变[M].中国实用妇产与产科杂志,2008,24(11)：808-810.
[10]HalstedWS. The results of operations for cancer of breast performed at the Johns Hopkins hospital from June1889 to January1889 [J].Joh Hop Bul,1894,4:294.
[11]Urban JA,Baker HW. Radical mastectomy with en bloc resection of the Intelmammary lymph node chain:a new procedure for primary operable cancer of the breast[J]. Cancer,1952,5 (5):992-1008.
[12]Fisher B, Jeong J H,Anderson S,et al.Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation[J]. N Engl J Med,2002,347 (8):567.
[13]王先明.乳腺癌手术治疗的历史演变与现代进展[J].中国现代手术学杂志,2003,7(6)：467-471.
[14]Smit JJ, SchinkelAH,Oude Elferink RPJ, et al. Homozygous disruption of the murine mdrz pglycop rotein gene leads to a comp lete absence of phospholip id from bile and to liver disease[J]. Cell,1993,75(3):451-462.
[15]Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer:long-term results of a randomized trial. Eur J Cancer,1990,26:668-670.
[16]Fisher B, Anderson S, Redmond CK, et al. Reanalysis and result s after 12 years of follow-up in a randomized clinical trial comparing total mastectomy wit h lumpectomy wit h orwit hout irradiation in the treatment of breast cancer [J]. NEngl J Med,1995; 333 (22):1456-1461
[17]National Surgical Adjuvant Breast and Bowel Project (NSABP). Progress Report [R]. July 1998:31-39.
[18]Sarrazin D, Arriagada R, Contesso G, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol,1989,14:177-184.
[19]Cutuli B,Nir CCS,Lafontan BD,et al.Brast-conserving therapy for ductal carcinoma in situ of the Breast:the French Cancer centers experience[J].Int J Radia Oncol Biol Phys,2002,53:868-879.
[20]Hiotic K,Ye W, Sposto R,et al.Predictors of breast conservation the rapy size is not all thatmatters[J]. Cancer,2005,103(5):892-899.
[21]叶再元,蒋劲松.乳腺癌外科治疗新进展[J].现代实用医学,2005,17(12)：730-732.
[22]郭小毛,梅欣等.局部晚期乳腺癌的治疗进展[J].中国癌症杂志,2006,16(6)：409-416.
[23]Reed J, Rosman M, Verbanac KM, et al. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer:10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study[J]. J Am Coll Surg,2009,208(3):333-340.
[24]Sato K, Shigenaga R. Sentinel lymph node biopsy for breast cancer[J]. J Surg Oncol,2007,96:322-329.
[25]邵志敏,沈镇宙.21世纪乳腺癌治疗的展望[M].中国癌症杂志,2005,15(5)： 405-407
[26]Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemot-herapy. Danish Breast Cancer Cooperative Group 8-b Trial [J]. N Engl J Med,1997; 337 (14):949-955.
[27]Whelan TJ,J ulian J,Wright J,et al.Does locoregional radiation therapy improve survival in breast cancer?A meta-analysis Ameta-analysis [J].J Clin Oncol, 2000; 18 (6):1220-1229.
[28]Recht A,Edge SB,Solin LJ,et al.Postmastectomy radiotherapy:clinical practice guidelines of the American Society of Clinical Oncology [J].J Clin Oncol,2001;19(5):1539-1569.
[29]于世英.放疗在乳腺癌治疗中作用[J].临床外科杂志,2000,8(5)：261.
[30]薛军,程晶等.不同放化疗模式治疗局部晚期乳腺癌的疗效分析[J].肿瘤防治研究,2009,36(10)：876-878.
[31]余子豪,乳腺癌.[M]殷蔚伯,谷铣之.肿瘤放射治疗学.3版.北京：中国协和医科大学出版社,2002：1077-1078.
[32]Early Breat Cancer TrialistsI Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:An overview of the randomised trials [J].Lancet,2005, 365 (9742):1687-1717.
[33]Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer the results of 20 years of follow-up [J]. N Engl J Med,1995,332 (14):901.
[34]Bonadonna G, Moliterni A, Zambetti M, et al.30 years follow up of randomized studies of adjuvant CMF in operable breast cancer, cohort study[J]. BMJ,2005,330:217.
[35]Early Breast Cancer Trialists's Collaborative Group. Multi-agent chemotherapy for early breast cancer [DB/CD]. Cochrane Database Syst Rev,2002, (1):CD000487.
[36]Poole CJ, Earl HM, Hiller L, et al.Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as adjuvant therapy for early breast cancer [J]. N Engl J Med,2006,355 (18):1851-1862.
[37]Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J].J Clin Oncol,2003,21 (6):976-983.
[38]Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after Doxorubicin plus Cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:Results from NSABP B-28 [J]. J Clin Oncol,2005,23 (16): 3686-3696.
[39]Jones S, Holmes F, O'Shaughnessy J, et al. Extended followup and analysis by age of the US oncology adjuvant trial 9735:Docetaxel/ Cyclophosphamide is associated with an OS benefit compared to Doxorubicin Cyclophosphamide and is welltolerated in women 65 or older. Paper presented at San Antonio Breast Cancer Symposium [C]. San Antonio, Texas, USA,2007.
[40]Jones SE, Savin MA, Holmes FA, et al. Phase Ⅲ trial comparing Doxorubicin plus Cyclophosphamide with Docetaxel plus Cyclophosphamide as adjuvant therapy for operable breast cancer [J]. J Clin Oncol,2006,24 (34): 5381-5387.
[41]Nabholtz JM, Pienkowski T, Mackey J, et al. Phase Ⅲ trial comparing TAC (Docetaxel, Doxorubicin, Cyclophosphamide) with FAC (5-Fluorouracil, Doxorubicin, Cyclophosphamide) in adjuvant treatment of node positive breast cancer patients:Interim analysis of the BCIRG 001 study [J]. Pro Am Soc Clin Oncol, 2002,21 (1):36.
[42]Ferguson T, Wilcken N, Vagg R, et al. Taxanes for adjuvant treatment of early breast cancer [DB/CD]. Cochrane Database Syst Rev,2007, (4): CD004421.
[43]PiccartMJ, Burzykowski T, Sledge G, et al. Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer: An analysis of 4,256 patients randomized in 12 trials [J]. Breast Cancer ResTreat, 2005,94:S278.
[44]Blum JL,DierasV,Lo Russo PM, et al. Multicenter, phase Ⅱ study of capecitabine in taxane-p retreated etastatic breast carcinoma patients [J]. Cancer, 2001,92:1759-1768.
[45]Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer[J]. Oncology,2001,15:11-14.
[46]FeherO,Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: A multicenter, randomized, phase Ⅲ study[J]. Ann Oncol,2005,16:899-908.
[47]Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase Ⅲ study of gemcitabine p lus paclitaxel (GT) vs paclitaxel (T) as frontline therapy formetastatic breast cancer (MBC):First report of overall survival [J]. Proc Am Soc Clin Oncol, 2004,23:5.
[48]Zelek L,Barthier S, RiofrioM, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma[J]. Cancer,2001,92:2267-2272.
[49]He L,Orr GA, Horwitz SB. Novelmolecules that interact with microtubules and have functional activity similar to Taxol[J]. Drug Discov Today,2001,6:1153-1164.
[50]GradisharW, Krasnojon D, Cheporov S, et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (p ts)with metastatic breast cancer (MBC) [J]. J Clin Oncol, 2007,25(18S):40 s.
[51]Early Breast Cancer Trialists'Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J]. Lancet,2005,365 (9472):1687-1717.
[52]Fisher B,Dignam J,Bryant J,et al. Five versus more t han five years of tamoxifen for lymph node2negative breast cancer:updated findings from the National Surgical Adjuvant Breast and Bowel Project B214 randomized t rial [J]. J N at l Cancer Ⅰ nst,2001,93 (9):684-690.
[53]MillerWR,Dixon JM. Local endocrine effects of aromatase inhibitorswith the breast[J. J Steroid Biochem Mol Biol,2001,79 (1/5):93-102.
[54]The ATAC Trialists Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:100-month analysis of the ATAC trial [J]. Lancet Oncol,2008,9(1):45-53.
[55]CoatesAS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study B IG 1-98 [J]. J Clin Oncol,2007,25 (5):486-492.
[56]王涛,江泽飞.早期乳腺癌术后辅助内分泌治疗的基本原则和新进展[M].肿瘤学杂志,2009,15(9)：783-787.
[57]Vogel C L, Cobleigh M A, Tripathy D, et al. Efficacy and safety of trast uzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol,2002, 20:719-726.
[58]Cameron D, Casey M, Press M, et al. A phase Ⅲ randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab:updated efficacy and biomarker analyses. Breast Cancer Res Treat,2008,112:533-543.
[59]Burris H 3rd, Yardley D, Jones S, et al. Phase Ⅱ trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol,2004,22:1621-1629.
[60]Geyer C E, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER222positive advanced breast cancer. N Engl J Med,2006,355:2733-2743.
[1]韩双红.蜈蚣的研究进展[J].天津药学,2002,14(5)：13-15.
[2]刘峰.蜈蚣的临床应用及毒性研究[J].广西中医药,1999,22(4)：52-53.
[3]杨永华,张水寒,徐琳本,等.僵蚕、蜈蚣提取工艺的研究[J].中国中药杂志,2001,26(9)：599-601.
[4]许鸣镝,柳雪枚.蜈蚣碱性蛋白SSmp-d的分离纯化及其部分理化性质的鉴定[J].生物化学杂志,1997,13(5)：586-591.
[5]曲爱兵,赵维成,梁良,等.蜈蚣组织提取物抗肿瘤活性的初步研究[J].实用肿瘤学杂志,2003,17(1)：29-30.
[6]迟程.墨江蜈蚣和少棘蜈蚣蚣总油脂化学成分比较[J].中草药,1992,23(2)：104.
[7]方红,邓芬,严宜昌,等.黑头蜈蚣的化学成分[J].中药材,1999,22(5)：226-228.
[8]方红,邓芬,严宜昌,等.多棘蜈蚣化学成分的研究[J].中国医学杂志,1997,32(4)；202-203.
[9]张保国,张大禄.动物药[M].北京：中国医药科技出版社,2003,875.
[10]肖培根.新编中药志(第四卷)[M].北京：化学工业出版社,2002,330.
[11]周莉莉,黄迎春,任超.蜈蚣醇提取物和水提取物部分药理作用比较[J].时珍国医国药,2008,19(11)：2697-8.
[12]迟程,罗天浩.蜈蚣毒性与用量的探讨[J].中国中药杂志,1995,15(6)：90-91.
[13]刘峰.蜈蚣的临床应用及其毒性研究[J].广西中医药,1999,22(4)：52-53.
[14]宋建徽,孟祥琴,王永利.蜈蚣提取液的中枢抑制作用及急性毒性[J].河北中医学院学报,1995,16(2)：91-92.
[15]韩双红.蜈蚣的研究进展[J].天津药学2002,14(5)：13-15.
[16]迟程,舒晔,迟萍.墨江蜈蚣和少棘蜈蚣抗惊厥药效学实验研究[J].云南中医学院学报,1992,15(1)：23-24.
[17]陈红琳,李小莉,甘明.墨江蜈蚣的药理作用[J].湖北中医杂志,2003,25(1)：501.
[18]司秋菊,王鑫国,白霞,等.蜈蚣对动脉粥样硬化家兔血液流变学的影响[J].中国老年学杂志,2004,24(9)：831-833.
[19]司秋菊,王亚利,王鑫国,等.蜈蚣有效成分抗心肌缺血作用的研究[J].河北中医药学报,2001,16(2)：1-3.
[20]司秋菊,王亚利,王鑫国,等.蜈蚣对心肌缺血性损伤小鼠NO及iNOS的影响[J].山东中医杂志,2004,23(8)：492-493.
[21]司秋菊,王鑫国,王亚利,等.蜈蚣对动脉粥样硬化家兔血管内皮细胞功能的影响[J].中药药理与临床,2002,18(6)：28-30.
[22]张艳慧,司秋菊,王鑫国.蜈蚣抗家兔动脉粥样硬化的实验研究[J].中药药理与临床2005；21(1)：26-27.
[23]王亚利,司秋菊,王鑫国,等.蜈蚣对动脉粥样硬化家兔血管平滑肌细胞周期及c-myc基因表达的影响[J].中药药床,2001,17(6)：28-29.
[24]张明泉,王亚利,温瑞书,等.蜈蚣提取液对大鼠心脏血流动力学的作用研究[J].河北中医,2004,26(9)：716-717.
[25]毛小平,陈子君,毛晓建,等.蜈蚣的部分药理研究[J].云南中医学院学报,1999,22(3)：1-4.
[26]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖南中医杂志,2004,20(5)：57-58.
[27]焦波,娄红祥,王东兴,等.蜈蚣提取液对小鼠精原细胞的作用[J].山东医科大学学报,1999,37(4)：358.
[28]李风云,陈浩然,张蓄兰,等.中药制剂抗肿瘤作用的实验研究[J].中医药学报,1999,27(5)：57.
[29]刘德贵,苗艳波,张铁光,等.简述有毒动物药的抗肿瘤作用临床研究[J].吉 林中医药,1998,18(6)：61.
[30]李厚伟,张妍,许超千,等.中药HB对喉癌Hep22细胞的抑制作用及其机制研究[J].哈尔滨医科大学学报,2001,35(4)：261-262.
[31]刘国清,田秉漳,皮执民,等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[32]冉泳禄,吴刚,王金焕,等.墨江蜈蚣与少棘蜈蚣的比较研究Ⅱ[J].动物学研究,1996,17(1)：79.
[33]贺巍,叶海英.中药蜈蚣的研究进展[J].中药材,2002,25(2)：152-155.
[34]毛小平,陈子珺,毛晓健,等.蜈蚣的部分药理研究[J].云南中医学院学报,1999,22(3)：1-3.
[35]李小莉,陈红林,甘民.不同品种蜈蚣的抗炎、镇痛作用[J].中国中药杂志,1996,21(8)：498.
[36]陈红琳,李小莉,甘明.墨江蜈蚣的药理作用[J].湖北中医杂志,2003,25(1)：50-51.
[37]梁洁,黄华营.药用蜈蚣的化学成分及药理活性研究近况[J].广西中医药[J]2005,28(4)：6-7.
[38]张维文,罗健东,张贵平.蜈蚣水提物对动物消化功能的增强作用.[J].中药材,1999,22(10)：518-519.
[39]朱步先.朱良春用药经验[M].上海：上海中医学院出版社,1989 120.
[40]王玉芬,韩双红,曲树明,等.蜈蚣延缓衰老作用的研究[J].中国中药杂志,1994,19(11)：685-687.
[41]任丽虹,郝立君,段国新,等.五倍子、蜈蚣对瘢痕疙瘩成纤维细胞增殖和胶原合成的影响[J].实用美容整形外科杂志,2003,14(6)：324-327.
[42]韩双红,王玉芬,赵泰,等.均肾舒冲剂药理作用的研究[J].中草药,1999,30(4)：282.
[43]方红,邓芬.蜈蚣药材中毒成分组织胺的含量测定[J].中草药,1997,28(8)：472-473.
[44]陶红.牵正蜈蚣散治疗神经系统疾病328例临床体会[J].湖南中医杂志,1990,6(1)：216.
[45]伍玉元.蜈蚣粉致急性肝功能损害2例[J].中国中药杂志,1994,19(1)：50.
[46]赵鹏俊,邹永祥.口服蜈蚣粉致急性肾功能衰竭死亡1例[J].中国中药杂志,1998,23(2)：117.
[47]肖贻纯.蜈蚣、全蝎致神经中毒1例[J].中国中药杂志,1996,21(10)：634.
[48]余圣龙.生蜈蚣致过敏[J].中国中药志,1989,14(5)：56.
[49]陈昕.蜈蚣过敏1例[J].四川中医,1997,15(10)：32.
[50]郭志达,吉小莉,宋建贞,等.中药蜈蚣对大鼠心脏毒性作用的初步研究[J].中国临床药理学与治疗学,2000；5(3)：278.
[51]邓芬,方红,王克勤.中药蜈蚣毒溶血活性试验[J].中药材,1997,20(1)：36-37.
[52]虞国茂,沈康.中药蜈蚣对小鼠胚胎发育的影响[J].解剖学杂志,1994,17(1)：56-59.
[53]迟程,罗天浩.蜈蚣毒性与用量的探讨[J].中国中药杂志,1995,15(6)：90-91.
[54]刘峰.蜈蚣的临床应用及其毒性研究[J].广西中医药,1999,22(4)：52-53.
[55]宋建徽,孟祥琴,王永利.蜈蚣提取液的中枢抑制作用及急性毒性[J].河北中医学院学报,1995,16(2)：91-92.
[56]李小莉,陈红琳,甘民.不同品种蜈蚣的抗炎、镇痛作用[J].中国中药杂志,1996,21(8)：498-499.
[57]韩双红.蜈蚣的研究进展[J].天津药学2002,14(5)： 13-15.